Outrage over High Drug Prices Continues, with New Focus on Specialties
Just three months ago I wrote two articles about the attention being paid to the skyrocketing costs of generics. Now, it seems, that outrage has been displaced by concerns over the high cost of specialty drugs that treat Hepatitis C, HIV, and Cancer.